IGF- 1 var normal ved undersøgelsens afslutning (i uge 12) hos henholdsvis 38, 5%, 75% og 82% af de patienter, der fik behandling med enten 10, 15 eller 20 mg/ dag SOMAVERT (sammenlignet med 9, 7% hos de patienter, der fik placebo).
IGF-I was normal at the end of the study (week 12) in 38.5%, 75% and 82% of patients treated with 10, 15 or 20 mg/ day SOMAVERT, respectively, compared with 9.7% of the patients treated with placebo.